The gold standard for treating Hodgkin`s disease patients: Where does ABVD acquire its evident superiority?

Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/11571

DC Field	Value	Language
dc.contributor.author	O. Karanfilski	en_US
dc.contributor.author	S. Stankovic	en_US
dc.contributor.author	T. Sotirova	en_US
dc.contributor.author	M. Pavkovic	en_US
dc.contributor.author	S. Trajkova	en_US
dc.contributor.author	A. Stojanovic	en_US
dc.date.accessioned	2021-03-26T12:32:00Z	-
dc.date.available	2021-03-26T12:32:00Z	-
dc.date.issued	2005	-
dc.identifier.uri	http://hdl.handle.net/20.500.12188/11571	-
dc.language.iso	en	en_US
dc.relation.ispartof	Haematologica	en_US
dc.subject	Morbus Hodgkin	en_US
dc.subject	ABVD protocol	en_US
dc.title	The gold standard for treating Hodgkin`s disease patients: Where does ABVD acquire its evident superiority?	en_US
dc.type	Proceeding article	en_US
dc.relation.conference	10-th Congress of European Hematology Association, Stockholm, Sweden, June 2-5, 2005	en_US
item.fulltext	With Fulltext	-
item.grantfulltext	open	-
crisitem.author.dept	Faculty of Medicine	-
crisitem.author.dept	Faculty of Medicine	-
crisitem.author.dept	Faculty of Medicine	-
crisitem.author.dept	Faculty of Medicine	-
crisitem.author.dept	Faculty of Medicine	-
Appears in Collections:	Faculty of Medicine: Conference papers